Joanne C, Paintaud G, Bresson-Hadni S, Magnette J, Becker M C, Miguet J P, Bechtel P R
Department of Clinical Pharmacology, CHU Jean Minjoz, Besançon, France.
Fundam Clin Pharmacol. 1994;8(1):76-9. doi: 10.1111/j.1472-8206.1994.tb00782.x.
Drug metabolism in the liver may be decreased during liver diseases. However, the extent of impairment of specific isozymes of cytochrome P450 is largely unknown. We have studied the debrisoquine hydroxylation capacity of 17 patients with acute viral hepatitis and 106 unrelated healthy subjects. Debrisoquine metabolic ratio was increased in extensive metabolizers (EM) with acute viral hepatitis as compared with healthy EMs (median metabolic ratio: 1.20 vs 0.84, P < 0.05). However, there was no difference in phenotype prevalence between patients and controls. Our results suggest that acute viral hepatitis only has a marginal effect on the activity of CYP2D6 and that substrates of this enzyme may be given in normal therapeutic doses to this category of patients.
肝脏疾病期间肝脏中的药物代谢可能会降低。然而，细胞色素P450特定同工酶的受损程度在很大程度上尚不清楚。我们研究了17例急性病毒性肝炎患者和106名无血缘关系的健康受试者的异喹胍羟化能力。与健康的强代谢者（EM）相比，急性病毒性肝炎的强代谢者的异喹胍代谢率升高（中位代谢率：1.20对0.84，P<0.05）。然而，患者和对照组之间的表型患病率没有差异。我们的结果表明，急性病毒性肝炎对CYP2D6的活性仅产生轻微影响，并且该酶的底物可以正常治疗剂量给予这类患者。
